Cargando…

Selective dopaminergic vulnerability in Parkinson’s disease: new insights into the role of DAT

One of the hallmarks of Parkinson’s disease (PD) is the progressive loss of dopaminergic neurons and associated dopamine depletion. Several mechanisms, previously considered in isolation, have been proposed to contribute to the pathophysiology of dopaminergic degeneration: dopamine oxidation-mediate...

Descripción completa

Detalles Bibliográficos
Autor principal:	Harraz, Maged M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483232/ https://www.ncbi.nlm.nih.gov/pubmed/37694119 http://dx.doi.org/10.3389/fnins.2023.1219441

Ejemplares similares

Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update
por: Brichta, Lars, et al.
Publicado: (2014)

Vulnerability of Mesostriatal Dopaminergic Neurons in Parkinson's Disease
por: González-Hernández, Tomás, et al.
Publicado: (2010)

Dopaminergic Control of Attentional Flexibility: Inhibition of Return is Associated with the Dopamine Transporter Gene (DAT1)
por: Colzato, Lorenza S., et al.
Publicado: (2010)

The Combination of DAT-SPECT, Structural and Diffusion MRI Predicts Clinical Progression in Parkinson’s Disease
por: Lorio, Sara, et al.
Publicado: (2019)

Roles of FGF20 in dopaminergic neurons and Parkinson's disease
por: Itoh, Nobuyuki, et al.
Publicado: (2013)

Dopamine compartmentalization, selective dopaminergic vulnerabilities in Parkinson's disease and therapeutic opportunities
por: Uhl, George R.
Publicado: (2019)

Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson’s Disease Motor Progression
por: Jackson, Holly, et al.
Publicado: (2021)

Neuropsychiatric Disorders in Parkinson’s Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?
por: Dujardin, Kathy, et al.
Publicado: (2020)

Parkinson’s disease: animal models and dopaminergic cell vulnerability
por: Blesa, Javier, et al.
Publicado: (2014)

Dopaminergic modulation of emotional conflict in Parkinson's disease
por: Fleury, Vanessa, et al.
Publicado: (2014)

Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease
por: Isaias, Ioannis U., et al.
Publicado: (2016)

Dopaminergic medication impairs feedback-based stimulus-response learning but not response selection in Parkinson's disease
por: Vo, Andrew, et al.
Publicado: (2014)

Influence of Depressive Symptoms on Dopaminergic Treatment of Parkinson’s Disease
por: Hanganu, Alexandru, et al.
Publicado: (2014)

Asymmetric Dopaminergic Degeneration and Attentional Resources in Parkinson’s Disease
por: Ortelli, Paola, et al.
Publicado: (2018)

Brain renin-angiotensin system and dopaminergic cell vulnerability
por: Labandeira-García, Jose L., et al.
Publicado: (2014)

Distinct Role of Striatal Functional Connectivity and Dopaminergic Loss in Parkinson’s Symptoms
por: Dukart, Juergen, et al.
Publicado: (2017)

Effect of Dopaminergic Medication on Postural Sway in Advanced Parkinson’s Disease
por: Revilla, Fredy J., et al.
Publicado: (2013)

Degeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson’s Disease
por: Song, Juhyun, et al.
Publicado: (2016)

Ca(V)1.3 L-Type Calcium Channels Increase the Vulnerability of Substantia Nigra Dopaminergic Neurons in MPTP Mouse Model of Parkinson’s Disease
por: Verma, Aditi, et al.
Publicado: (2020)

The Effect of Dopaminergic Medication on Beat-Based Auditory Timing in Parkinson’s Disease
por: Cameron, Daniel J., et al.
Publicado: (2016)

Dopaminergic and Opioid Pathways Associated with Impulse Control Disorders in Parkinson’s Disease
por: Erga, Aleksander H., et al.
Publicado: (2018)

Dopaminergic and Metabolic Correlations With Cognitive Domains in Non-demented Parkinson’s Disease
por: Han, Linlin, et al.
Publicado: (2021)

Differential dopaminergic modulation of spontaneous cortico–subthalamic activity in Parkinson’s disease
por: Sharma, Abhinav, et al.
Publicado: (2021)

Calbindin content and differential vulnerability of midbrain efferent dopaminergic neurons in macaques
por: Dopeso-Reyes, Iria G., et al.
Publicado: (2014)

Evidence That Substantia Nigra Pars Compacta Dopaminergic Neurons Are Selectively Vulnerable to Oxidative Stress Because They Are Highly Metabolically Active
por: Ni, Anjie, et al.
Publicado: (2022)

Voice Analysis to Differentiate the Dopaminergic Response in People With Parkinson's Disease
por: Jain, Anubhav, et al.
Publicado: (2021)

Editorial: Parkinson's disease: cell vulnerability and disease progression
por: Blesa, Javier, et al.
Publicado: (2015)

Dopaminergic and Clinical Correlates of Pathological Gambling in Parkinson’s Disease: A Case Report
por: Callesen, Mette Buhl, et al.
Publicado: (2013)

Molecular Imaging of Striatal Dopaminergic Neuronal Loss and the Neurovascular Unit in Parkinson Disease
por: Ivanidze, Jana, et al.
Publicado: (2020)

Src Inhibition Attenuates Neuroinflammation and Protects Dopaminergic Neurons in Parkinson’s Disease Models
por: Yang, Hanyu, et al.
Publicado: (2020)

Negative DAT‐SPECT in Old Onset Parkinson's Disease: An Additional Pitfall?
por: Palermo, Giovanni, et al.
Publicado: (2022)

Sexual dysfunction precedes motor defects, dopaminergic neuronal degeneration, and impaired dopamine metabolism: Insights from Drosophila model of Parkinson’s disease
por: Koza, Zevelou, et al.
Publicado: (2023)

Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson's disease induced presynaptic alterations
por: Fu, Jessie Fanglu, et al.
Publicado: (2019)

Habitual behavior and dopamine cell vulnerability in Parkinson disease
por: Hernández, Ledia F., et al.
Publicado: (2015)

Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease
por: Greenbaum, Lior, et al.
Publicado: (2013)

Early Degeneration of Both Dopaminergic and Serotonergic Axons – A Common Mechanism in Parkinson’s Disease
por: Grosch, Janina, et al.
Publicado: (2016)

Dopaminergic Therapy Increases Go Timeouts in the Go/No-Go Task in Patients with Parkinson’s Disease
por: Yang, Xue Q., et al.
Publicado: (2018)

EEG Microstates Change in Response to Increase in Dopaminergic Stimulation in Typical Parkinson’s Disease Patients
por: Serrano, J. Ignacio, et al.
Publicado: (2018)

Smilagenin Protects Dopaminergic Neurons in Chronic MPTP/Probenecid—Lesioned Parkinson’s Disease Models
por: He, Xuan, et al.
Publicado: (2019)

A Multi-Scale Computational Model of Excitotoxic Loss of Dopaminergic Cells in Parkinson's Disease
por: Muddapu, Vignayanandam Ravindernath, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pnbpu8fgsmujisiarjfj545ob7